These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 3207527)

  • 1. Relative bioavailability of controlled release morphine tablets (MST continus) in cancer patients.
    Poulain P; Hoskin PJ; Hanks GW; A-Omar O; Walker VA; Johnston A; Turner P; Aherne GW
    Br J Anaesth; 1988 Nov; 61(5):569-74. PubMed ID: 3207527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories.
    Du X; Skopp G; Aderjan R
    Ther Drug Monit; 1999 Apr; 21(2):208-14. PubMed ID: 10217341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain.
    Moolenaar F; Meijler WJ; Frijlink HW; Visser J; Proost JH
    Eur J Clin Pharmacol; 2000 Jun; 56(3):219-23. PubMed ID: 10952476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose and steady-state kinetics of morphine and its metabolites in cancer patients--a comparison of two oral formulations.
    Hasselström J; Alexander N; Bringel C; Svensson JO; Säwe J
    Eur J Clin Pharmacol; 1991; 40(6):585-91. PubMed ID: 1653145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine.
    Somogyi AA; Nation RL; Olweny C; Tsirgiotis P; van Crugten J; Milne RW; Cleary JF; Danz C; Bochner F
    Clin Pharmacokinet; 1993 May; 24(5):413-20. PubMed ID: 8504624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients.
    Klepstad P; Dale O; Kaasa S; Zahlsen K; Aamo T; Fayers P; Borchgrevink PC
    Acta Anaesthesiol Scand; 2003 Jul; 47(6):725-31. PubMed ID: 12803591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients.
    Wilkinson TJ; Robinson BA; Begg EJ; Duffull SB; Ravenscroft PJ; Schneider JJ
    Cancer Chemother Pharmacol; 1992; 31(3):251-4. PubMed ID: 1464164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain.
    Goucke RC; Hackett PL; Ilett KF
    Pain; 1994 Feb; 56(2):145-149. PubMed ID: 8008404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral morphine in cancer pain: influences on morphine and metabolite concentration.
    McQuay HJ; Carroll D; Faura CC; Gavaghan DJ; Hand CW; Moore RA
    Clin Pharmacol Ther; 1990 Sep; 48(3):236-44. PubMed ID: 2401122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.
    Quigley C; Joel S; Patel N; Baksh A; Slevin M
    Palliat Med; 2003 Mar; 17(2):185-90. PubMed ID: 12701850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma morphine-3-glucuronide, morphine-6-glucuronide and morphine concentrations in patients receiving long-term epidural morphine.
    Schneider JJ; Ravenscroft PJ; Cavenagh JD; Brown AM; Bradley JP
    Br J Clin Pharmacol; 1992 Nov; 34(5):431-3. PubMed ID: 1467139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphine and morphine-glucuronide concentrations in plasma and CSF during long-term administration of oral morphine.
    van Dongen RT; Crul BJ; Koopman-Kimenai PM; Vree TB
    Br J Clin Pharmacol; 1994 Sep; 38(3):271-3. PubMed ID: 7826830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations.
    Hasselström J; Säwe J
    Clin Pharmacokinet; 1993 Apr; 24(4):344-54. PubMed ID: 8491060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients.
    Wolff T; Samuelsson H; Hedner T
    Pain; 1996 Dec; 68(2-3):209-16. PubMed ID: 9121807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis.
    Pauli-Magnus C; Hofmann U; Mikus G; Kuhlmann U; Mettang T
    Nephrol Dial Transplant; 1999 Apr; 14(4):903-9. PubMed ID: 10328468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine.
    Stuart-Harris R; Joel SP; McDonald P; Currow D; Slevin ML
    Br J Clin Pharmacol; 2000 Mar; 49(3):207-14. PubMed ID: 10718775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration.
    Wolff T; Samuelsson H; Hedner T
    Pain; 1995 Aug; 62(2):147-154. PubMed ID: 8545139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy.
    Holthe M; Klepstad P; Zahlsen K; Borchgrevink PC; Hagen L; Dale O; Kaasa S; Krokan HE; Skorpen F
    Eur J Clin Pharmacol; 2002 Aug; 58(5):353-6. PubMed ID: 12185559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of morphine slow release tablet (MST) and morphine sulphate solution (MSS) in the treatment of cancer pain.
    Panich A; Charnvej L
    J Med Assoc Thai; 1993 Dec; 76(12):672-6. PubMed ID: 7798818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers.
    Hoskin PJ; Hanks GW; Aherne GW; Chapman D; Littleton P; Filshie J
    Br J Clin Pharmacol; 1989 Apr; 27(4):499-505. PubMed ID: 2719903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.